Key facts
- It has raised $98.0M across 2 recorded rounds; the latest was Later Stage VC (Series C) ($98.0M) in Aug 2020.
- Kinnate Biopharma has filed 3 Form Ds with the SEC since 2019, most recently Aug 2020 ($98.0M sold to 24 investors).
Free account
See the evidence behind this price
- ·Post-money valuations for all 2 rounds
- ·Watchlist + deal alerts for Kinnate Biopharma
Create free account
No card required
Funding rounds
2 roundsAug 2020Later Stage VC (Series C)$98.0M▮
About Kinnate Biopharma
- Industry
- Drug Discovery
PA Mark — not yet priced
Kinnate Biopharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Pro members can request priority coverage with a 48-hour turnaround.
Recorded secondary trades
No prints on record
No secondary trades in Kinnate Biopharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
No fund marks yet
No SEC-registered fund has reported a fair-value mark on Kinnate Biopharma in its N-PORT filings yet. We sweep new filings monthly.
Pro members can request priority coverage with a 48-hour turnaround.